UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q
 
þ
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the quarterly period ended SeptemberFOR THE QUARTERLY PERIOD ENDED JUNE 30, 20142015

OR

oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period fromFOR THE TRANSITION PERIOD FROM __________ toTO _________

COMMISSION FILE NUMBER: 000-25132

MYMETICS CORPORATION
(Exact name of registrant as specified in its charter)
 
DELAWARE  25-1741849
(State or other jurisdiction of incorporation or organization)  (I.R.S. Employer Identification No.)
 
c/o Mymetics S.A.
Biopole
Route de la Corniche, 4
1066 Epalinges (Switzerland)
(Address of principal executive offices)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: 011 41 21 653 4535
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þNo o
             
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þNo o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “accelerated filer,” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
 
Large Accelerated Filer
o 
Accelerated Filero
o
 
Non-Accelerated Filer
o 
Smaller Reporting Companyþ
þ
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes oNo þx
                                             
Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date:
 
Class Outstanding at November 13, 2014August 14, 2015
Common Stock, $0.01 par value 303,757,622
 
 
 
 
 
 
PART I.    FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MYMETICS CORPORATION
CONSOLIDATED BALANCE SHEETS
 (UNAUDITED)
(In Thousands of Euros)
 
 September 30, December 31,  June 30, December 31, 
 2014 2013  2015 2014 
   (audited)      
ASSETS          
Current Assets          
Cash E1,343 E297  E3,164 E1,614 
Receivable other  311  3,712   350  278 
Prepaid expenses  68  57   51  52 
Total current assets  1,722  4,066   3,565  1,944 
              
Property and equipment, net of accumulated depreciation of E311 at September 30, 2014 and E287 at December 31, 2013  109  117 
Property and equipment, net of accumulated depreciation of E330 at June 30, 2015 and E311 at December 31, 2014  117  129 
In-process research and development  2,266  2,266   2,266  2,266 
Goodwill  6,671  6,671   6,671  6,671 
 E10,768 E13,120  E12,619 E11,010 
              
          
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)          
Current Liabilities              
Deferred revenue from grants E1,517 E309 
Accounts payable E539 E858   754  416 
Acquisition-related contingent consideration  --  236 
Current portion of convertible notes payable to related parties  39,642  39,123 
Total current liabilities  40,181  40,217 
Convertible notes payable to related parties  41,845  40,374 
Total liabilities  44,116  41,099 
              
              
Shareholders' Equity (Deficit)              
Common stock, U.S. $0.01 par value; 850,000,000 shares authorized; issued 303,757,622 at September 30, 2014 and 298,418,813 at December 31, 2013  2,529  2,491 
Preferred stock, U.S. $0.01 par value; 5,000,000 shares authorized; none issued or Outstanding  --  -- 
Common stock, U.S. $0.01 par value; 850,000,000 shares authorized; issued 303,757,622 at June 30, 2015 and at December 31, 2014  2,530  2,530 
Preferred stock, U.S. $0.01 par value; 5,000,000 shares authorized; none issued or outstanding  --  -- 
Additional paid-in capital  34,155  33,876   34,255  34,169 
Accumulated deficit  (66,742)  (64,165)  (68,937)  (67,421)
Accumulated other comprehensive income  645  701   655  633 
  (29,413)  (27,097)  (31,497)  (30,089)
 E10,768 E13,120  E12,619 E11,010 

The accompanying notes are an integral part of these financial statements.

 
2
 
 
MYMETICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
 (UNAUDITED)
(In Thousands of Euros, Except Per Share Data)
 
  For The Three Months Ended September 30,  For The Nine Months Ended September 30, 
  2014  2013  2014  2013 
             
Revenue            
Sales E--  E165  E--  E165 
Research and development support  635   --   1,677   -- 
Government grants  --   (3)  --   (3)
   635   162   1,677   162 
Expenses                
Research and development  396   (89)  1,137   159 
General and administrative  369   197   1,043   941 
Bank fee  --   1   2   3 
Interest  642   674   1,954   1,951 
Change in the fair value of acquisition-                
  related contingent consideration  --   (9)  --   (6,292)
Depreciation  8   5   24   15 
Directors' fees  5   5   15   15 
Other  68   (55)  53   5 
   1,488   729   4,228   (3,204)
Income (loss) before income tax provision  (853)  (567)  (2,551)  3,366 
Income tax provision  (2)  (4)  (26)  (11)
Net income (loss)  (855)  (571)  (2,577)  3,355 
Other comprehensive income (loss)                
Foreign currency translation adjustment  (29)  (3)  (56)  28 
Comprehensive income (loss) E(884) E(574) E(2,633) E3,383 
                 
Basic and diluted net income (loss) per share E(0.00) E(0.02) E(0.01) E0.01 
  
For The Three Months Ended
June 30,
  
For The Six Months Ended
June 30,
 
  2015  2014  2015  2014 
             
Revenue            
Research and Development services E552  E515  E1,162  E1,042 
Grants  476   --   528   -- 
   1,028   515   1,690   1,042 
Expenses                
Research and development  554   372   921   741 
General and administrative  447   292   840   674 
Bank fee  1   1   2   2 
Depreciation  9   9   19   16 
Directors' fees  5   5   10   10 
Foreign exchange and other  (75)  3   118   (15)
   941   682   1,910   1,428 
Income (Loss)  87   (167)  (220)  (386)
                 
Interest Expense  643   634   1,286   1,312 
Loss before income tax provision  (556)  (801)  (1,506)  (1,698)
                 
Income tax provision  (7)   (12)   (10)   (24) 
Net Loss  (563)  (813)  (1,516)  (1,722)
                 
Other comprehensive Loss                
Foreign currency translation adjustment  (41)  (9)  22   (27)
Comprehensive Loss E(604) E(822) E(1,494) E(1,749)
                 
                 
Basic earnings per share E(0.00) E(0.00) E(0.00) E(0.01)
Diluted earnings per share E(0.00) E(0.00) E(0.00) E(0.01)
 
The accompanying notes are an integral part of these financial statements.

 
3
 

MYMETICS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In Thousands of Euros)
 
 
For The Nine Months Ended
September 30,
  
For The Six Months Ended
June 30,
 
 2014 2013  2015 2014 
          
Cash Flow from Operating Activities          
Net income (loss) E(2,577) E3,355 
Adjustments to reconcile net income (loss) to net cash used in operating activities     
Change in the fair value of acquisition-related contingent consideration -- (6,292) 
Net loss E(1,516) E(1,722)
Adjustments to reconcile net loss to net cash provided by operating activities     
Depreciation 24 14  19 16 
Stock compensation expense – options 81 3  86 56 
Changes in operating assets and liabilities          
Receivables 3,401 4   (72)  3,432 
Accrued interest on notes payable 1,471 1,287 
Deferred revenue from grants 1,208 -- 
Accounts payable (319)  (868) 338 (406)
Other  (11)   589   1  (44)
Net cash provided by (used in) operating activities  599   (3,195)
Net cash provided by operating activities  1,535   2,619 
     
Cash Flows from Investing Activities          
Purchase of property and equipment  (16)   (77)   (7)   (13) 
Net cash provided by (used in) investing activities  (16)  (77) 
Net cash used in investing activities  (7)  (13) 
     
Cash Flows from Financing Activities          
Increase in notes payable and other short-term advances 2,057 4,912 
Decrease in notes payable and other short-term advances  (1,538)   (1,151 )
Payments on notes payable and other short-term advances  --  (1,538)
Net cash used in financing activities 519 3,761   --  (1,538) 
     
Effect on foreign exchange rate on cash  (56)  28   22   (27)
Net change in cash 1,046 517   1,550  1,041 
     
Cash, beginning of period  297  286   1,614  297 
Cash, end of period E1,343 E 803  E3,164 E 1,338 
          
Supplemental Disclosure of Cash Flow Information:          
Cash Paid for Interest E76 E --  E-- E 76 
     
Supplemental Disclosure of Non-cash Financing Activities:     
Issuance of 5,338,809 shares of common stock to settle acquisition-Related contingent consideration E236 E -- 

The accompanying notes are an integral part of these financial statements.
 
 
4
 
 
MYMETICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
SEPTEMBERJUNE 30, 20142015
(UNAUDITED)
 
Note 1. The Company and Summary of Significant Accounting Policies
 
BASIS OF PRESENTATION

The amounts in the notes are shown in thousands of EURO rounded to the nearest thousand except for share and per share amounts.

The accompanying interim period consolidated financial statements of Mymetics Corporation (the "Company") set forth herein have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosure normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted pursuant to such SEC rules and regulations. The interim period consolidated financial statements should be read together with the audited financial statements and the accompanying notes included in the Company's latest annual report on Form 10-K for the fiscal year ended December 31, 2013.2014.

The accompanying financial statements of the Company are unaudited. However, in the opinion of the Company, the unaudited consolidated financial statements contained herein contain all adjustments necessary to present a fair statement of the results of the interim periods presented. All adjustments made during the three-month period ending SeptemberJune 30, 20142015 were of a normal and recurring nature.
 
Mymetics Corporation (and its subsidiaries) is an early stage biotechnology company focused on(the "Company" or "Mymetics") was created for the purpose of engaging in vaccine research and development of vaccines for infectious diseases. Mymetics’ core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. The Company’s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine.development. Its main research efforts to date have been concentrated in the prevention and treatment of the Respiratory Syncytial Virus (RSV), the AIDS virus and malaria. The Company has established a network which enables it to work with education centers, research centers, pharmaceutical laboratories and biotechnology companies. On April 1, 2009 the Company successfully closed its acquisition of Bestewil Holding BV and Mymetics currentlyBV (previously Virosome Biologicals BV) and, as a result, has fivefurther increased the pipeline of vaccines in its pipeline: HIV-1/AIDS, intra nasal Influenza, Malaria,under development to include (i) Herpes Simplex which is at the pre-clinical stage, (ii) intranasal influenza for elderly which has finished a clinical trial Phase I, and (iii) Respiratory Syncytial Virus (RSV) which is at the pre-clinical stage. On December 27, 2013, Mymetics signed a License and Collaboration Agreement with RSV Corporation (RSVC), a dedicated entity specifically set-up for developing the Mymetics RSV vaccine. Under this agreement Astellas Pharma Inc. will fund RSVC’s development of the virosome vaccine technology, licensed from Mymetics for the respiratory syncytial virus (RSV) through completion of a Phase 2b human proof‐of‐concept study. Based on the strategic partnership, Astellas received exclusive rights to acquire RSVC as well as further develop and commercialize the vaccine product. Mymetics will continue to provide research and development activities for the pre-clinical phases and prepare for the upscale production, assay developments and provide further scientific advice on the development of the RSV vaccine (out licensed to ClearPath – Astellas). The Company’s intranasal Influenza vaccinevirosome vaccine. As consideration Mymetics has received an irrevocable and non-refundable upfront fee for the HIV-1 vaccine have successfully completed Phase I clinical trials in healthy human volunteers. A Phase 1b clinical triallicense of USD 5 million and will receive monthly Collaboration and R&D fees, milestone payments for its Malaria vaccine on children in Tanzania has been completed, whilespecific milestones during development and royalties at the HSV vaccine candidate is in the preclinical phase.time of commercialization.

As of SeptemberJune 30, 2014,2015, the Company is in the pre-clinical testing of some of its vaccine candidates and a commercially viable product is not expected for several more years. However, the Company generates some revenue through the licensing of its RSV vaccine and from collaboration agreements for R&D services. Management believes that the Company’s research and development activities will result in valuable intellectual property that can generate significant revenues in the future such as by licensing. Vaccines are one of the fastest growing markets in the pharmaceutical industry.

These consolidated financial statements have been prepared assuming the Company will continue as a going concern. DeficitsThe Company has experienced significant losses since inception resulting in operating cash flows have been financed through debt and equity funding sources. In order to remain a going concern and continue the Company's research and development activities, management intends to seek additional funding either through collaboration agreements or direct investments.an accumulated deficit of E68,937 at June 30, 2015. Further, the Company’s current liabilities exceed its current assets by E38,459E40,551 as of SeptemberJune 30, 2014,2015, and there is no assurance that cash will become available to pay current liabilities in the near term. Management is seeking additional financing but there can be no assurance that management will be successful in any of those efforts. These conditions raise substantial doubt about our ability to continue as a going concern.
  
PRINCIPLES OF CONSOLIDATION
 
The consolidated financial statements include the accounts of the Company and its subsidiaries. Significant intercompany accounts and transactions have been eliminated.

5
FOREIGN CURRENCY TRANSLATION
 
The Company translates non-Euro assets and liabilities of its subsidiaries at the rate of exchange at the balance sheet date. Revenues and expenses are translated at the average rate of exchange throughout the period. Unrealized gains or losses from these translations are reported as a separate component of comprehensive income. Transaction gains or losses are included in general and administrative expenses in the consolidated statements of operations. The translation adjustments do not recognize the effect of income tax because the Company expects to reinvest the amounts indefinitely in operations. The Company's reporting currency is the Euro because substantially all of the Company's activities are conducted in Europe.

5
CASH
 
Cash deposits are occasionally in excess of insured amounts.

REVENUE RECOGNITION

Exclusive Licenses
 
The deliverables under an exclusive license agreement generally include the exclusive license to the Company’s technology, and may also include deliverables related to research activities to be performed on behalf of the collaborative collaborator and the manufacture of preclinical or clinical materials for the collaborative collaborator.
 
Generally, exclusive license agreements contain non-refundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) provide research services which are reimbursed at a contractually determined rate which includes margin for the Company, (ii) participate in a joint steering committee to monitor the progress of the research and development which will be reimbursed at a contractually determined rate which includes margin for the Company, (iii) earn payments upon the achievement of certain milestones and (iv) earn royalty payments at the time of commercialization until the later of expiration of the last to expire valid patent rights expire or 10 years after the first commercial sale. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements.  The Company does not directly control when any collaborator will request research or manufacturing services, achieve milestones or become liable for royalty payments. As a result, the Company cannot predict when it will recognize revenues in connection with any of the foregoing.
 
The Company follows the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, "Revenue Recognition—Multiple-Element Arrangements," and ASC Topic 605-28, "Revenue Recognition—Milestone Method," in accounting for these agreements.  In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on if certain criteria are met, including whether the delivered element has stand-alone value to the collaborator.  The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Factors considered in this determination include the research and manufacturing capabilities of the collaborator and the availability of technology research expertise in the general marketplace.

RSV Corporation

In December 2013, the Company entered into an agreement with RSV Corporation. The agreement provides RSV Corporation with an exclusive license to the Company’s RSV technology in order to develop and commercialize respiratory syncytial virus virosome vaccines. The Company received a US$5 million upfront payment in connection with the execution of the agreement and the Company is entitled to receive milestone payments potentially totaling $62$77 million plus royalties on product sales, if any. The Company also is entitled to receive payments for research and development activities performed on behalf of RSV Corporation. RSV Corporation is responsible for the development, manufacturing, and marketing of any products resulting from this agreement.

In accordance with ASC 605-25, the Company identified all of the deliverables at the inception of the agreement. The significant deliverables were determined to be the RSV technology license and the research and development services including participation on the Joint Collaboration and Steering Committee (JCSC). The Company has determined that the RSV technology license does have standalone value from the research services. As a result, the research services are considered a separate unit of accounting. The estimated selling prices for these units of accounting were determined based on market conditions and entity-specific factors such as the terms of the collaborators’ previous collaborative agreements, recent preclinical and clinical testing results of therapeutic products that use the Company’s RSV technology, the Company’s pricing practices and pricing objectives, and the nature of the research services to be performed for RSV Corporation and market rates for similar services. The arrangement consideration was allocated to the deliverables based on the relative selling price method. The Company recognized license revenue when the exclusive license was delivered pursuant to the terms of the agreement which was upon execution of the agreement. The Company does not control when RSV Corporation will reach certain development and commercialization’s milestones related to the RSV technology. As a result, the Company cannot predict when or if it will recognize the related milestone and royalty revenue. The Company will recognize research services revenue as the related services are delivered.

 
6
 
 
Fixed price contracts and research and collaboration agreements

When the performance under a fixed price contract can be reasonably estimated, revenue for such a contract is recognized under the proportional performance method and earned in proportion to the contract costs incurred in performance of the work as compared to total estimated contract costs. Costs incurred under fixed price contracts represent a reasonable measurement of proportional performance of the work. Direct costs incurred under collaborative research and development agreements are recorded as research and development expenses. If the performance under a fixed price contract cannot be reasonably estimated, the Company recognizes the revenue on a straight-line basis over the contract term.

IMUGENE Limited
 
In July 2014, the Company entered into a master service agreement with Imugene Limited. The agreement provides the terms and conditions upon which Imugene Limited may engage the Company to provide services to produce specific virosomesvirosome based HER2/neu positive cancer vaccines by executing individual Work Orders with fixed price agreements. In consideration for the exclusive supply rights granted by the Company to Imugene, the Company received options to purchase 2.5 million common shares of Imugene with an exercise price of AUD 0.025 per share with an exercise period of 5five years, and is entitled to receive milestone payments potentially totaling CHF 2.8 million (None due yet) plus royalties on product sales, if any. The value of the options received is insignificant and has not been recorded as of September 30, 2014.recorded. The Company also is entitled to receive payments for research and development activities performed on behalf of Imugene. The Company recognizes revenue under the proportional performance method.

TEXAS BIOMEDICAL RESEARCH INSTITUTE
 
In September 2014, the Company entered into a material transfer agreement and fixed price contract with Texas Biomedical Research Institute. The agreement provides Texas Biomedical Research Institute the lead of a project which has been proposed to the Bill and Melinda Gates foundation with the objective to confirm previous results obtained in non humannon-human primates with these virosome based HIV vaccine candidates. The Company has tested these different formulations of virosome based HIV vaccines candidates in preclinical non humannon-human primate studies and in Phase I clinical settings. The value of the options received is insignificant, and has not been recorded as of September 30, 2014. The Company will produce and transfer to Texas Biomedical Research Institute the original material using the Company’s background IP. The Company will recognizerecognizes revenue under the proportional performance method.
PATH-MVI
In November 2014, the Company signed an agreement with PATH Malaria Vaccine Initiative (MVI) and the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), where Mymetics will develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate which will be based on two antigens provided by LMIV. The vaccine formulations will then be tested in animal models. PATH MVI will fund all activities under this project, which started in January 2015. The Company recognizes revenue under the proportional performance method.

HORIZON 2020-SERI
In April 2015, the Company was selected to receive project grants with a total of E8.4 million. A total of E5.3 million is funded as part of Horizon 2020, the European Union research and innovation framework program and up to E3.1 million of funding will be provided by the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. The grant will fund the evaluation, development and manufacturing scale-up of thermo stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Of the total amount, E3.4 million is directly attributable to Mymetics activities, with the remaining balance going to the consortium partners, Catalent UK Swindon Zydis Ltd, Chimera Biotec GmbH (Germany), Upperton Ltd. (UK) and Bachem AG (Switzerland). The project duration is 42 months and started on May 4, 2015. In May 2015, the Company has received a pre-payment from the two granting organizations for a total value of E1.5 million. The Company recognizes revenue under the proportional performance method and recognized E219 for the three months ending June 30, 2015. The remaining amount received has been recorded as deferred revenue.

RECEIVABLES
 
Receivables are stated at their outstanding principal balances. Management reviews the collectability of receivables on a periodic basis and determines the appropriate amount of any allowance. There was no allowance necessary at SeptemberJune 30, 20142015 or December 31, 2013.2014. The Company charges off receivables to the allowance when management determines that a receivable is not collectible. The Company may retain a security interest in the products sold.

PROPERTY AND EQUIPMENT
 
Property and equipment is recorded at cost and is depreciated over its estimated useful life on straight-line basis from the date placed in service. Estimated useful lives are usually taken as three years.

7
IN-PROCESS RESEARCH AND DEVELOPMENT
 
In-process research and development (“(referred to as IPR&D”)&D) represents the estimated fair value assigned to research and development projects acquired in a purchased business combination that have not been completed at the date of acquisition and which have no alternative future use. IPR&D assets acquired in a business combination are capitalized as indefinite-lived intangible assets. These assets remain indefinite-lived until the completion or abandonment of the associated research and development efforts. During the periods prior to completion or abandonment, those acquired indefinite-lived assets are not amortized but are tested for impairment annually, or more frequently, if events or changes in circumstances indicate that the asset might be impaired.

7
IMPAIRMENT OF LONG LIVED ASSETS
 
Long-lived assets, which include property and equipment, are assessed for impairment whenever events or changes in circumstances indicate the carrying amount of the asset may not be recoverable. The impairment testing involves comparing the carrying amount to the forecasted undiscounted future cash flows generated by that asset. In the event the carrying value of the assets exceeds the undiscounted future cash flows generated by that asset and the carrying value is not considered recoverable, impairment exists. An impairment loss is measured as the excess of the asset’s carrying value over its fair value, calculated using a discounted future cash flow method. An impairment loss would be recognized in net income in the period that the impairment occurs.
GOODWILL
 
Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis as of April 1 of each year, unless events or circumstances indicate impairment may have occurred before that time. The Company assesses qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount. After assessing qualitative factors, the Company must determine if further testing was necessary. If further testing was necessary, the Company would have performed a two-step impairment test for goodwill. The first step requires the Company to determine the fair value of each reporting unit. To the extent a reporting unit’s carrying amount exceeds its fair value, an indication exists that the reporting unit’s goodwill may be impaired and the Company must perform a second more detailed impairment assessment. The second impairment assessment involves allocating the reporting unit’s fair value to all of its recognized and unrecognized assets and liabilities in order to determine the implied fair value of the reporting unit’s goodwill as of the assessment date. The implied fair value of the reporting unit’s goodwill is then compared to the carrying amount of goodwill to quantify an impairment charge as of the assessment date.
 
The Company has conducted its impairment testing as of April 1, of 20142015 and 20132014 of its goodwill recognized in connection to the acquisition of Bestewil. In conclusion of this impairment testing, the carrying amount of the reporting unit was lower than the estimated fair value of the reporting unit. As the fair value of the reporting unit is higher than the carrying amount, Step 2 of the goodwill impairment test did not need to be completed. As of SeptemberJune 30, 2014,2015, management believes there are no indications of impairment.

CONTINGENT CONSIDERATION
The Company accounts for contingent consideration in a purchase business combination in accordance with applicable guidance provided within the business combination rules. As per the agreement, which was last amended on February 3, 2014, the Company settled the contingent consideration liability with issuance of 5,338,809 shares of common stock in April 2014.

RESEARCH AND DEVELOPMENT
 
Research and development costs are expensed as incurred.
 
TAXES ON INCOME
 
The Company accounts for income taxes under an asset and liability approach that requires the recognition of deferred tax assets and liabilities for expected future tax consequences of events that have been recognized in the Company's financial statements or tax returns. In estimating future tax consequences, the Company generally considers all expected future events other than enactments of changes in the tax laws or rates.
 
The Company reports a liability, if any, for unrecognized tax benefits resulting from uncertain income tax positions taken or expected to be taken in an income tax return. Estimated interest and penalties, if any, are recorded as a component of interest expense and other expense, respectively.
 
The Company has not recorded any liabilities for uncertain tax positions or any related interest and penalties at SeptemberJune 30, 20142015 or at December 31, 2013.2014.  The Company’s United States tax returns are open to audit for the years ended December 31, 20092010 to 2013. The returns for the Luxembourg subsidiary LUXEMBOURG 6543 S.A., are open to audit for the year ended December 31, 2013.2014. The returns for the Swiss subsidiary, Mymetics S.A., are open to audit for the years ended December 31, 20092011 to 2013.2014. The returns for the Netherlands subsidiaries, Bestewil B.V. and Mymetics B.V., are open to audit for the year ended December 31, 2013.2014.

8
EARNINGS PER SHARE
 
Basic earnings per share is computed by dividing net income or loss attributable to common shareholders by the weighted average number of common shares outstanding in the period. Diluted earnings per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. For the quarter ended SeptemberJune 30, 2013,2015, options, warrants and convertible debt were not included in the computation of diluted earnings per share under the treasury stock method because their effect would be anti-dilutive due to net losses incurred. For the nine months period ending September 30, 2013, there were no potential issuable shares included in the diluted earnings per share calculation as the conversion price of those instruments were all out-of-the-money. For the three and nine months ended September 30, 2014, options, warrants and convertible debt were not included in the computation of diluted earnings per share because their effect would be anti-dilutive due to net losses incurred under the treasury stock method.
 
For the three and ninesix months ended SeptemberJune 30, 2014,2015, the basic weighted average number of shares was 303,757,622,303,757,622. The total potential number of shares issuable of 532,284,571 at June 30, 2015 includes 502,584,571 potential issuable shares related to convertible loans, and 301,782,458,29,700,000 potential issuable shares related to outstanding stock options granted to employees.
For the three and six months ended June 30, 2014, the basic weighted average number of shares was 303,112,271, and 300,778,508, respectively. The weighted total potential number of shares issuable of 495,832,109486,606,984 includes 474,982,109465,756,984 potential issuable shares related to convertible loans, and 20,850,000 potential issuable shares related to outstanding not expired options granted to employees.

8
For the three and nine months ended September 30, 2013, the weighted average number of shares was 295,318,813. For the same periods, the total potential number of shares issuable of 441,680,054 includes 438,330,054 potential issuable shares related to convertible loans and 3,350,000 potential issuable shares related to outstanding not expired options granted to employees.
 
PREFERRED STOCK
 
The Company has authorized 5,000,000 shares of preferred stock that may be issued in several series with varying dividend, conversion and voting rights. No preferred shares are issued or outstanding at SeptemberJune 30, 2015 or December 31, 2014.

STOCK-BASED COMPENSATION
 
Compensation cost for all share-based payments is based on the estimated grant-date fair value. The Company amortizes stock compensation cost ratably over the requisite service period.
 
The issuance of common shares for services is recorded at the quoted price of the shares on the date the shares are issued. As part of the 2013 stock option plan, the Company issued 8,850,000 shares to individuals in the three and six months ended June 30, 2015. No shares were issued to individuals as fee for services rendered in the ninesix months ended September 30, 2014 or in the nine months ended September 30, 2013.
For the year ended December 31 2013, the Board of Directors of Mymetics awarded 20,600,000 incentive stock options to the employees and officers of the Company which were awarded on October 4, 2013 with an exercise price of USD 0.02 per share. 3,300,000 incentive stock options vested immediately, of which 3,100,000 were exercised as of December 31, 2013, and 17,300,000 vest in equal quantities over the next four years.
The Company did not grant any stock options to employees during the nine month period ending SeptemberJune 30, 2014.
 
Stock compensation expense amounted to E28E71 and NILE28 during the three monthsmonth periods ended SeptemberJune 30, 20142015 and 2013,2014, respectively, and E81E86 and E3E56 during the nine monthssix month periods ended SeptemberJune 30, 20142015 and 2013,2014, respectively, which is included in the statementstatements of operations within general and administrative expenses.
 
ESTIMATES
 
The preparation of financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

FAIR VALUE MEASUREMENTS
 
Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

Level  1:
Level 1-Quoted prices in active markets for identical assets or liabilities.
Level 2-Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
 
Level  2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level  3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

FAIR VALUES OF FINANCIAL INSTRUMENTS
 
The Company generally has the following financial instruments: cash, receivables, accounts payable, acquisition-related contingent consideration, and notes payable. The carrying value of cash, receivables and accounts payable, approximates their fair value based on the short-term nature of these financial instruments. The carrying value of acquisition-related contingent consideration is equal to fair value since this liability is required to be reported at fair value. Management believes that it is not practicable to estimate the fair value of the notes payable due to the unique nature of these instruments.

 
9
 
 
CONCENTRATIONS
 
The Company enters into scientific collaboration agreements with selected partners such as Pevion Biotech Ltd.(“Pevion”), a Swiss company that granted Mymetics exclusive licenses to use their virosome vaccine delivery technology in conjunction with the Company’s AIDSderived 67% and malaria preventive vaccines under development. Under this agreement, Pevion was committed to supply the actual Virosomes and perform their integration with the Company’s antigens, which requires proprietary know-how, at Pevion’s premises.  The agreement included specific mechanisms to mitigate the risk100% of losing a key component of Mymetics’ vaccines should Pevion become unable to meet its commitment.
During the year ended December 31, 2013, Pevion initiated a process of winding down and communicated their inability to continue to supply the virosomes needed for the HIV and malaria vaccines. Mymetics has taken the necessary steps to ensure the continuing supply of virosomes needed for the HIV and malaria vaccines. Mymetics terminated its agreements with Pevion in January 2014. Operations between Pevion and Mymetics had substantially ceased in 2013. Mymetics retained knowledge, rights and access to production and development of the HIV and malaria virosome vaccines by hiring key personnel.
In 2013 and 2014, the Company derived most of licensing revenue from its relationship with one collaborative partner RSV Corporation. Most ofduring the researchsix month periods ended June 30, 2015 and development support employed inJune 30, 2014, is from the same collaborative partner.respectively. Furthermore, that same collaborative partner accounted for 98%60% and 79% of the receivables balance at June 30, 2015 and December 31, 2013 and 80% of the receivables balance at September 30, 2014.2014, respectively.

RELATED PARTY TRANSACTIONS
 
An individual employed by the law firm that acts as the Company's general counsel is a member of the Board of Directors. The Company incurred professional fees to the counsel's law firm totaling E14E7 and E39E25 for the period of three and ninesix months ending SeptemberJune 30, 20142015 and E92E13 and E177E86 for three and ninesix months ending SeptemberJune 30, 2013,2014, respectively.

NEW ACCOUNTING PRONOUNCEMENTS
In June 2014, the FASB issued ASU 2014-10, "Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation". The amendments in this ASU remove all incremental financial reporting requirements from GAAP for development stage entities, including the removal of Topic 915, "Development Stage Entities", from the FASB Accounting Standards Codification. In addition, this ASU adds an example disclosure and removes an exception provided to development stage entities in Topic 810, "Consolidation,” for determining whether an entity is a variable interest entity. The presentation and disclosure requirements in Topic 915 will no longer be required for the first annual period beginning after December 15, 2014. The revised consolidation standards are effective for annual periods beginning after December 15, 2015. Early adoption is permitted. Mymetics has decided to adopt these standards starting in this reporting period.
 
In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. ASU 2014-09 is effective for the fiscal and interim reporting periods beginning after December 15, 20162017 using either of two methods:

(i)  retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or

(ii)  retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09.
 
Management is currently evaluating the impact of the Company's pending adoption of ASU 2014-09 on its consolidated financial statements.
 
Note 2. Intangible Assets
 
Intangible assets consisted of in process research and development at SeptemberJune 30, 20142015 and December 31, 2013.2014.

10
Note 3. Acquisition-Related Contingent Consideration
On April 1, 2009 Mymetics and Norwood Immunology Limited (“NIL”) closed the acquisition of Bestewil Holding B.V. (“Bestewil”) from its parent, NIL, under a Share Purchase Agreement pursuant to which Mymetics agreed to purchase all issued and outstanding shares of capital stock (the “Bestewil Shares”) of Bestewil from its parent, NIL, and all issued and outstanding shares of capital stock of Virosome Biologicals B.V. which were held by Bestewil. Mymetics paid NIL E5,000 (the “Cash Consideration”) raised from bridge financing (the “Bridge Loan”) and issued to NIL a convertible redeemable note (the “Note”) in the principal amount of E2,500 due 36 months after the closing date, bearing interest at 5% per annum, convertible into shares of the Company’s common stock at a conversion rate of $0.50 (“the Conversion Price” since September 2010) and secured by the Company’s pledge of 1/3rd of the Bestewil Shares. The reduction of the Conversion price from $0.80 to $0.50 in September 2010 did not result in an extinguishment and reissuance of the note, nor did it result in a material adjustment in the consolidated financial statements. In addition, Mymetics granted NIL an option to acquire shares of Mymetics common stock equal to the result obtained by dividing $9,609 by the Conversion Price. As part of the Share Purchase Agreement, if Mymetics had issued shares of capital stock in connection with a financing to repay the Bridge Loan that had more favorable financial rights and preferences than the original conversion price or other terms, NIL had the right, at its election, to acquire those shares at the better terms. The difference in the fair value of the shares issuable based on the terms of the original conversion price and the fair value of the shares actually issued based on the inducement terms was recorded as an expense of E807 during 2010.
On March 28, 2013, Mymetics agreed with NIL to amend the terms and conditions of the E2,500 loan that expired on March 31, 2013. Under the terms of the Amendment, Mymetics agreed to make a series of payments as follows to release it from any obligation to share future revenues from the sale of Mymetics' intranasal influenza vaccine, RSV vaccine and HSV vaccine: (i) by April 30, 2013 E521 consisting of E500 of principal under the Loan Note and E21 of accrued interest for the month of April 2013 on the outstanding principal balance of E2,500 (ii) by May 31, 2013 E517 consisting of E500 of principal under the Loan Note and E17 of accrued interest for the month of May 2013 on the outstanding principal balance of E2,000, (iii) by September 30, 2013 accrued interest of E51 on the outstanding principal balance of E1,500 under the Loan Note and (iv) by March 31, 2014 E1,576 consisting of E1,500 to extinguish the outstanding principal balance of the Loan Note and E76 to extinguish the remaining unpaid accrued interest owed on the outstanding principal balance of the Loan Note. The Company fully repaid the note and accrued interest during the nine months ended September 30, 2014.
The following table presents changes to the Company’s acquisition-related contingent consideration for the periods ending September 30, 2014 and 2013:
  Fair Value Measurements Using Significant 
  Unobservable Inputs(Level 3) 
  Acquisition-related Contingent Consideration 
       
  
September 30,
2014
  
September 30,
2013
 
       
Balance at January 1 E236  E6,533 
Settlement of liability E(236)   -- 
Change in fair value  --   (6,292)
Balance at September 30 E--  E241 
During the nine month period ending September 30, 2013, the fair value of the acquisition-related contingent consideration was fully adjusted down based on amendment to the Share Purchase Agreement, and settled with issuance of shares for a total of $325,000 in April 2014.
Note 4. Debt Financing
 
Certain principal shareholders have granted the Company secured convertible notes (in accordance with the Uniform Commercial Code in the State of Delaware) and short term convertible notes, which have a total carrying value of E39,642E41,845 including interest due to date. Interest incurred on these notes since inception has been added to the principal amounts.
 
 
1110
 
 
The details of the convertible notes and loans are as follows at SeptemberJune 30, 2014:2015:

             Fixed            Fixed 
          Conversion  Rate          Conversion Rate 
Lender 1st-Issue Principal  Duration Interest Price  EUR/USD  1st-Issue Principal Duration Interest Price EUR/USD 
Price Date Amount  (Note) Rate (stated)  Conversion  Date Amount (Note) Rate (stated) Conversion 
                            
Eardley Holding A.G. (1) 06/23/2006 E150   (2)10% pa $0.10   N/A  06/23/2006 E171 (2) 10% pa $0.10 N/A 
Anglo Irish Bank S.A.(3) 10/21/2007 E500   (2)10% pa $0.50   1.4090  10/01/2007 E500 (2) 10% pa $0.50 1.4090 
Round Enterprises Ltd. 12/10/2007 E1,500   (2)10% pa $0.50   1.4429  12/10/2007 E1,500 (2) 10% pa $0.50 1.4429 
Round Enterprises Ltd. 01/22/2008 E1,500   (2)10% pa $0.50   1.4629  01/22/2008 E1,500 (2) 10% pa $0.50 1.4629 
Round Enterprises Ltd. 04/25/2008 E2,000   (2)10% pa $0.50   1.5889  04/25/2008 E2,000 (2) 10% pa $0.50 1.5889 
Round Enterprises Ltd. 06/30/2008 E1,500   (2)10% pa $0.50   1.5380  06/30/2008 E1,500 (2) 10% pa $0.50 1.5380 
Round Enterprises Ltd. 11/18/2008 E1,200   (2)10% pa $0.50   1.2650  11/17/2008 E1,200 (2) 10% pa $0.50 1.2650 
Round Enterprises Ltd. 02/09/2009 E1,500   (2)10% pa $0.50   1.2940  02/06/2009 E1,500 (2) 10% pa $0.50 1.2940 
Round Enterprises Ltd. 06/15/2009 E5,500   (2,4)10% pa $0.80   1.4045  06/15/2009 E5,500 (2,4) 10% pa $0.80 1.4045 
Eardley Holding A.G. 06/15/2009 E100   (2,4)10% pa $0.80   1.4300  06/15/2009 E100 (2,4) 10% pa $0.80 1.4300 
Von Meyenburg 08/03/2009 E200   (2)10% pa $0.80   1.4400  08/03/2009 E200 (2) 10% pa $0.80 1.4400 
Round Enterprises Ltd. 10/13/2009 E2,000   (2)5% pa $0.25   1.4854  10/13/2009 E2,000 (2) 5% pa $0.25 1.4854 
Round Enterprises Ltd. 12/18/2009 E2,200   (2)5% pa $0.25   1.4338  12/18/2009 E2,200 (2) 5% pa $0.25 1.4338 
Round Enterprises Ltd. 08/04/2011 E946   (5,6)10% pa $0.034   N/A  08/04/2011 E1,082 (5,6) 10% pa $0.034 N/A 
Eardley Holding A.G. 08/04/2011 E236   (5,6)10% pa $0.034   N/A  08/04/2011 E270 (5,6) 10% pa $0.034 N/A 
Round Enterprises Ltd. 11/08/2011 E400   (6)10% pa $0.034   1.3787  11/08/2011 E400 (6) 10% pa $0.034 1.3787 
Eardley Holding A.G. 11/08/2011 E100   (6)10% pa $0.034   1.3787  11/08/2011 E100 (6) 10% pa $0.034 1.3787 
Round Enterprises Ltd. 02/10/2012 E1,000   (6)10% pa $0.034   1.3260  02/10/2012 E1,000 (6) 10% pa $0.034 1.3260 
Eardley Holding A.G. 02/14/2012 E200   (6)10% pa $0.034   1.3260  02/14/2012 E200 (6) 10% pa $0.034 1.3260 
Round Enterprises Ltd. 04/19/2012 E322   (6)10% pa $0.034   1.3100  04/19/2012 E322 (6) 10% pa $0.034 1.3100 
Eardley Holding A.G. 04/19/2012 E80   (6)10% pa $0.034   1.3100  04/19/2012 E80 (6) 10% pa $0.034 1.3100 
Round Enterprises Ltd. 05/04/2012 E480   (6)10% pa $0.034   1.3152  05/04/2012 E480 (6) 10% pa $0.034 1.3152 
Eardley Holding A.G. 05/04/2012 E120   (6)10% pa $0.034   1.3152  05/04/2012 E120 (6) 10% pa $0.034 1.3152 
Round Enterprises Ltd. 09/03/2012 E200   (6)10% pa $0.034   1.2576  09/03/2012 E200 (6) 10% pa $0.034 1.2576 
Eardley Holding A.G. 09/03/2012 E50   (6)10% pa $0.034   1.2576  09/03/2012 E50 (6) 10% pa $0.034 1.2576 
Round Enterprises Ltd. 11/14/2012 E500   (6)10% pa $0.034   1.2718  11/04/2012 E500 (6) 10% pa $0.034 1.2718 
Eardley Holding A.G. 12/06/2012 E125   (6)10% pa $0.034   1.3070  12/06/2012 E125 (6) 10% pa $0.034 1.3070 
Round Enterprises Ltd. 01/16/2013 E240   (6)10% pa $0.034   1.3318  01/16/2013 E240 (6) 10% pa $0.034 1.3318 
Eardley Holding A.G. 01/16/2013 E60   (6)10% pa $0.034   1.3318  01/16/2013 E60 (6) 10% pa $0.034 1.3318 
Round Enterprises Ltd. 03/25/2013 E400   (6)10% pa $0.037   1.2915  03/25/2013 E400 (6) 10% pa $0.037 1.2915 
Eardley Holding A.G. 04/14/2013 E150   (6)10% pa $0.034   1.3056  04/14/2013 E150 (6) 10% pa $0.034 1.3056 
Round Enterprises Ltd. 04/14/2013 E600   (6)10% pa $0.034   1.3056  04/14/2013 E600 (6) 10% pa $0.034 1.3056 
Eardley Holding A.G. 05/15/2013 E170   (6)10% pa $0.037   1.2938  05/15/2013 E170 (6) 10% pa $0.037 1.2938 
Round Enterprises Ltd. 05/15/2013 E680   (6)10% pa $0.037   1.2938  05/15/2013 E680 (6) 10% pa $0.037 1.2938 
Eardley Holding A.G. 06/24/2013 E60   (6)10% pa $0.025   1.3340  06/24/2013 E60 (6) 10% pa $0.025 1.3340 
Round Enterprises Ltd. 06/24/2013 E240   (6)10% pa $0.025   1.3340  06/24/2013 E240 (6) 10% pa $0.025 1.3340 
Eardley Holding A.G. 08/05/2013 E80   (6)10% pa $0.018   1.3283  08/05/2013 E80 (6) 10% pa $0.018 1.3283 
Round Enterprises Ltd. 08/05/2013 E320   (6)10% pa $0.018   1.3283  08/05/2013 E320 (6) 10% pa $0.018 1.3283 
Total Short Term Principal Amounts   E27,609                 E27,800          
Accrued Interest   E12,033                 E14,045          
TOTAL LOANS AND NOTES TO RELATED PARTIES   E39,642              
              
TOTAL LOANS AND NOTES   E41,845          
 
(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.

(2) This maturity date is automatically prolonged for periods of three months, unless called for repayment.

(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

(4) The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV and against all property of the Company.

(5) The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively.

(6) This maturity date is automatically prolonged for periods of three months, unless called for repayment. The conversion price per share is determined by the lower of (i) reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with an investment in the Company of not less than $20,000.
Note 5. Equity FinancingUS$20,000, or (ii) at the stated conversion price using a fixed exchange rate which are noted in the table above.

The Company is in discussions with certain potential investors and lenders to obtain financing and meet the Company’s expenses during fiscal year 2015 and beyond.
 
1211
 

ITEM  2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
ITEM  2.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

GENERAL

The following discussion and analysis of the results of operations and financial condition of Mymetics Corporation for the periods ended SeptemberJune 30, 20142015 and 20132014 should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 20132014 and related notes and the description of the Company's business and properties included elsewhere herein.

This report contains forward-looking statements that involve risks and uncertainties. The statements contained in this report are not purely historical, but are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These forward looking statements concern matters that involve risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. Words such as "may," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue", "probably" or similar words are intended to identify forward looking statements, although not all forward looking statements contain these words.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We are under no duty to update any of the forward-looking statements after the date hereof to conform such statements to actual results or to changes in our expectations.

Readers are urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation disclosures made under the captions "Management Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Consolidated Financial Statements" and "Notes to Consolidated Financial Statements" included in our annual report on Form 10-K for the year ended December 31, 20132014 and, to the extent included therein, our quarterly reports on Form 10-Q filed during fiscal year 2014.2015.

THREE MONTHS ENDED SEPTEMBERJUNE 30, 20142015 AND 20132014

Revenue was E635E1,028 and E515 for the three months ended SeptemberJune 30, 2015 and 2014, respectively. The E1,028 consisted of which E536 relatesE552 related to the research and development services provided under a License and Collaboration Agreement for the RSV vaccine and E99 related to the Master Service Agreement signed on July 14th, 2014 with Imugene Limited, compared to E165December 23, 2013 and E476 from the grant revenue recognized for the three months ended September 30, 2013.HIV and malaria projects.

Costs and expenses increased to E1,488E941 for the three months ended SeptemberJune 30, 20142015 from E729 (104.1%E682 (38.0%) for the three months ended SeptemberJune 30, 2013, Mainly2014 mainly due to reversal of scientific cost provision in 2013, an increase in scientific resourcesboth general and consulting cost related to the RSV projectadministrative costs and the Imugene agreement during the three months ended September 30, 2014in research and foreign exchange revaluation of USD position to Euro.development costs.

Research and development expenses increased to E396E554 in the current period from (E89) (544.9%E372 (48.9%) in the comparative period of 2013. The increase of R&D2014. This is mainly due to reversal of scientific cost provision in 2013 and anthe increase in scientific resources and consultinglaboratory cost relatednecessary to the RSVMACIVIVA project with Horizon 2020/SERI, the malaria project with MVI - PATH and Imugene projects incurred during the three months ended September 30, 2014.HIV project with Texas Biomedical.
 
General and administrative expenses increased to E369E447 in the three months ended SeptemberJune 30, 20142015 from E197 (87.3%E292 (53.1%) in the comparative period of 2013. Mainly2014. This is due to indemnity received from liability insurance duringseveral additional cost incurred this year, such as; stock option expenses increase related to new issuances; additional marketing cost related to the three months ended September 30, 2013.projects press releases; new contract with exclusive financial advisor; company website design and increase in laboratory space in Leiden.

Interest expenseOther expenses decreased to E642E(75) for the three months ended SeptemberJune 30, 2015 from E3 (-2600.0%) for the six months ended June 30, 2014, mainly due to the foreign exchange revaluation of existing US$ based loans from E674third party investors.

Interest expense increased to E643 for the three months ended SeptemberJune 30, 2013. This is mainly due to interests of E39 incurred during2015 from E634 for the three months ended SeptemberJune 30, 20132014 related to existing loans from third party investors.

The Company reported a net loss of (E563), or (E0.00) per share, for the three months ended June 30, 2015, compared to a net loss of (E813), or (E0.00) per share, for the three months ended June 30, 2014.
SIX MONTHS ENDED JUNE 30, 2015 AND 2014
Revenue was E1,690 and E1,042 for the six months ended June 30, 2015 and 2014, respectively. The E1,690 was related to the research and development services provided under a License and Collaboration Agreement for the RSV vaccine signed on December 23, 2013 and E528 was related to the grant revenue recognized for the HIV and malaria projects.
12
Costs and expenses increased to E1,910 for the six months ended June 30, 2015 from E1,428 (33.8%) for the six months ended June 30, 2014, mainly due to an increase in general and administrative costs and research and development costs.

Research and development expenses increased to E921 in the current period from E741 (24.3%) in the comparative period of 2014, due to the additional work related to the MACIVIVA project with Horizon 2020/SERI, the malaria project with MVI -PATH and the HIV project with Texas Biomedical.
General and administrative expenses increased to E840 in the six months ended June 30, 2015 from E674 (24.6%) in the comparative period of 2014. This is due to legal cost provision reversal in the six month period ended June 30, 2014, and several additional cost incurred this year, such as; stock option expenses increase related to new issuances; additional marketing cost related to the projects press releases; new contract with exclusive financial advisor; company website design and increase in laboratory space in Leiden.

Other expenses increased to E118 for the six months ended June 30, 2015 from E(15) (886.7%) for the six months ended June 30, 2014, mainly due to the foreign exchange revaluation of existing US$ based loans from third party investors.

Interest expense decreased to E1,286 for the six months ended June 30, 2015 from E1,312 for the six months ended June 30, 2014 related to existing loans from third party investors and related Norwood Immunology loan of E1,500, which has been settled on March 31,st , 2014.

The Company reported a net loss of (E853)(E1,516), or (E0.00) earnings per share, for the threesix months ended SeptemberJune 30, 2014,2015, compared to a net loss of (E567)(E1,722), or (E0.02) earnings(E0.01) per share, for the threesix months ended September 30, 2013.
NINE MONTHS ENDED SEPTEMBER 30, 2014 AND 2013
Revenue was E1,677 for the nine months ended September 30, 2014, of which E1,578 relates to the research and development provided under a License and Collaboration Agreement for the RSV vaccine and E99 related to the Master Service Agreement signed on July 14th, 2014 with Imugene Limited, compared to E165 for the nine months ended September 30, 2013.
13
Costs and expenses increased to E4,228 for the nine months ended September 30, 2014 from (E3,204) (-232.0%) for the nine months ended September 30, 2013, mainly due to the E6,292 write off of the acquisition-related contingent consideration in the nine month period ending September 30, 2013.
Research and development expenses increased to E1,137 in the current period from E159 (615.1%) in the comparative period of 2013. The increase of R&D is mainly due to the RSV vaccine project, which requires additional resources and consulting costs, and the reversal of scientific cost provision in the nine months ended September 30, 2013.
General and administrative expenses increased to E1,043 in the nine months ended September 30, 2014 from E941 (10.8%) in the comparative period of 2013. This is mainly due to legal indemnity paid which has been partially covered by the liability insurance, increase in related legal cost incurred in the nine months ended September 30, 2013 and legal cost provision reversal in the nine months ended SeptemberJune 30, 2014.
 
Interest expense increased to E1,954 for the nine months ended September 30, 2014 from E1,951 for the nine months ended September 30, 2013.
As per the amendment of the Norwood Immunology (“NIL”) contract signed on March 25, 2013 and subsequent amendment signed on February 3, 2014, the Company has paid back the remaining part of the loan with NIL and the accrued interest. In April 2014, Mymetics issued NIL 5,338,809 shares of Mymetics common stock, thereby eliminating completely the contingent consideration liability.
The Company reported a net loss of (E2,577), or (E0.01) earnings per share, for the nine months ended September 30, 2014, compared to a net income of E3,355, or E0.01 earnings per share, for the nine months ended September 30, 2013.

LIQUIDITY AND CAPITAL RESOURCES

We had cash of E1,343E3,164 at SeptemberJune 30, 20142015 compared to E297E1,614 at December 31, 2013.2014.

On December 27, 2013, Mymetics has entered in to a License and Collaboration Agreement (“LCA”) with RSV Corporation (“RSVC”) to license Bestewil Holding BV, a 100% subsidiary of Mymetics’ Corporation virosome technology related to developing, commercializing respiratory syncytial virus (RSV) virosome vaccines for the purpose of development and eventual commercialization, which will generate revenue to support the running cost of Bestewil Holding BV.
On July 14, 2014, Mymetics has entered into a master service agreement with Imugene Limited (“Imugene”). The agreement provides the terms and conditions upon which Imugene may engage the Company to provide services to produce specific virosomes based HER2/neu positive cancer vaccines by executing individual Work Orders and provides Mymetics the possibility to receive milestone and royalty payments in the future.
On September 25, 2014, Mymetics has entered into a material transfer agreement with the Texas Biomedical Research Institute. The agreement provides Texas Biomedical Research Institute (“Texas Biomed”) the lead of a project which has been accepted for funding the Bill and Melinda Gates Foundation with the objective to confirm previous results obtained by Mymetics in non human primates with these virosome based HIV vaccine candidates. The Company has tested these different formulations of virosome based HIV vaccines candidates in preclinical non human primate studies and in Phase I clinical settings. Mymetics will produce the vaccine formulations and provide these to Texas Biomed who will execute the study.

As of SeptemberJune 30, 2014,2015, we had an accumulated deficit of approximately E67E69 million, and had net loss of E2,577E1,516 in the ninesix month period ending on that date. We expect to continue to incur expensesnet losses in the future for research, development and activities related to the future licensing of our technologies.technologies, and because of the accrual of interest payable on existing loans.

Net cash provided in operating activities was E599E1,535 for the ninesix month period ended SeptemberJune 30, 2015 due to the pre-payment received related to the MACIVIVA project from the Swiss and EU granting organizations. During the six month period ending June 30, 2014 net cash provided in operating activities was E2,619 due to the decrease in receivables after having received the upfront cash payment related to the LCA, compared to net cash used of (E3,195) for the period ended September 30, 2013.LCA.

Investing activities used cash of (E16)(E7) during the ninesix months ended SeptemberJune 30, 2014,2015, compared to (E77)(E13) for the comparable period in 2013,2014, all related to the purchase of equipment for our laboratory in Leiden.

Financing activities for the ninesix months ended SeptemberJune 30, 2015 is NIL compared to (E1,538) of cash used for the six month period ended June 30, 2014, of cash provided is E519, mainly duerelated to the accrued interests on shareholder loans of E2,057 reduced by the repayment of the NIL loan and accumulated interests of E1,538, compared to E3,761 of cash provided for the nine months ended September 30, 2013.a loan.

14
Salaries and related payroll costs represent gross salaries for two executives, our CSO of Mymetics BV and sevennine employees. Under Executive Employment Agreements with our CEO and two CSOs, we pay our executive officers a combined amount of E51E65 per month.

In addition, ourOur Swiss subsidiary, Mymetics S.A., has two employees on its payroll: Director of Finance and Head of Manufacturing and Quality. Mymetics BV has, besides the full time Chief Scientific Officer, sevensix full-time assistants and one part-time assistant.

We intend to continue to incur additional expenditures during the next 12 months for additional research and development of RSV vaccine as per the LCA with RSVC.RSVC and for the development of our HIV and Malaria vaccine candidates, which are funded through agreements the Bill and Melinda Gates Foundation and PATH MVI, respectively. Additionally we have started the MACIVIVA project for the research and development of thermo stable vaccines. These expenditures will relate to the continued testing of its prototype vaccines and are included in the monthly cash outflow described above. In parallel we are seekingcontinuing to seek partnerships and grant funding for our HIV and Malaria vaccines.vaccine development activities.
13
 
In the past, we have financed our research and development activities primarily through debt and equity financings from various parties.
On June 19, 2015, the registrant, through its wholly-owned Swiss subsidiary, Mymetics SA ("Mymetics") entered into an Agreement with Breslin AG ("Breslin"), under which Breslin agrees to serve as the exclusive advisor to advise and support Mymetics in finding an industry partner to assist with the further development of the intranasal flu vaccine program which had successfully completed a clinical Phase I trial.  Solvay Pharmaceuticals, which was acquired by Abbott Laboratories in 2009, was a prior partner of Mymetics for the intranasal flu vaccine and had successfully completed a clinical Phase I trial with 100 patients but transferred the partnering rights back to Mymetics following a strategic refocusing by Abbott Laboratories.  Under the terms of the Agreement, Mymetics has agreed to pay to Breslin a retainer of €7,500 per month for six months, capped at €45,000, in addition to certain success fees for potential upfront and milestone payments and royalties based upon potential sales of Mymetics' intranasal flu vaccine product.
 
We anticipate that our normal operations will require approximately E1,200E3 million in the year ending December 31, 2014.2015, which is financed by the research and development services and the grant agreements we have signed. We will seek to raise the requiredadditional capital from equity or debt financings, and grants through donors and potential partnerships with major international pharmaceutical and biotechnology firms. However, there can be no assurance that we will be able to raise additional capital on satisfactory terms, or at all, to finance our operations. In the event that we are not able to obtain such additional capital, we will be required to further restrict or even cease our operations.
 
Monthly fixed and recurring expenses for "Property leases" of E13E14 represent the monthly lease and maintenance payments to unaffiliated third parties for our offices, of which E4 is related to our executive office located at Route de la Corniche 4, 1066 Epalinges in Switzerland (100 square meters), and E9E10 related to Bestewil Holding B.V. and its subsidiary Mymetics B.V operating from a similar biotechnology campus near Leiden in the Netherlands, where they occupy 178150 square meters.
 
Included in professional fees are legal fees paid to outside corporate counsel and audit and review fees paid to our independent accountants, and fees paid for investor relations.
 
Cumulative interest expense of E12,033E14,045 has been accrued on all of the Company’s outstanding notes and advances (see detailed table in Note 43 to the financial statements).

RECENT FINANCING ACTIVITIES
 
During the ninesix month period ending SeptemberJune 30, 2014,2015, our principal source of funds has been revenues related to a License and Collaboration Agreement (“LCA”) with RSV Corporation (“RSVC”) signed on December 27, 2013 to license Bestewil Holding BV IP and the delivery of R&D services and the master service agreement with Imugene Ltd. which was signed on July 14, 2014.
On September 25, 2014, Mymetics has entered into a master transfer agreement with Texas Biomedical Research Institute for a project funded by the Bill and Melinda Gates Foundation. The objective of this project is to confirm previous results obtained by Mymetics in non human primates with virosome based HIV vaccine candidates. The project will start in October 2014 and is planned to end in the third quarter of 2015 and it will provide Mymetics grant revenue for the production of the virosomes and the participation in the project.BV.
 
We have filed aor are in the process of filing several new grant applicationapplications with U.S. and European institutions in relation to our HIV and malaria vaccines.
 
We anticipate using our current funds and those we receive in the future both to meet our working capital needs and for funding the ongoing vaccines pre-clinical research costs associated with our gp41 testing. Provided we can obtain sufficient financing resources, we expect to continue the development for RSV, malaria and HIV vaccine candidates and start to develop new vaccine candidates on our proprietary virosome vaccine technology in 2015. In accordance with our past strategy, we intend to subcontract such work to "best of class" research teams unless institutions such as the US National Institutes of Health (NIH) decide to conduct such trials at their own expense, which they presently do. vaccine.
 
We do anticipateManagement anticipates that our existing capital resources will be sufficient to fund our cash requirements through the next sixtwelve months. However,We have enough cash presently on hand in conjunction with the collection of receivables, based upon our current levels of expenditures and anticipated needs during this period. For 2016 we will need additional proceeds from additionalfunding through future collaborative arrangements, licensing arrangements, and debt and equity investments such as private placementsfinancings under Regulation D and Regulation S under the Securities Act of 1933. We do not know whether additional financing will be available on commercially acceptable terms when needed.
 
If management cannot raise funds on acceptable terms when needed, we may not be able to successfully commercialize our technologies, take advantage of future opportunities, or respond to unanticipated requirements. If unable to secure such additional financing when needed, we will have to curtail or suspend all or a portion of our business activities and could be required to cease operations entirely. Further, if new equity securities are issued, our shareholders may experience severe dilution of their ownership percentage.

15
 
The extent and timing of our future capital requirements will depend primarily upon the rate of our progress in the research and development of our technologies, our ability to enter into one or more licensing ora partnership agreementsagreement with a major pharmaceutical companies,company, and the results of our present and future clinical trials.
With the out-licensing and collaboration agreement for our RSV vaccine candidate, we are generating some revenue, but this is not covering the cost of all our operations. We are unable to predict when or if we will be able to generate more revenues from licensing our technology or the amounts expected from such activities. These new revenue streams may be generated by us or in conjunction with collaborative partners or third party licensing arrangements, and may include provisions for one-time, lump sum payments in addition to ongoing royalty payments or other revenue sharing arrangements. However, we presently have no commitments for any such payments.

OFF-BALANCE SHEET ARRANGEMENTS
 
The Company does not have any off-balance sheet arrangements.
 
14
ITEM 3.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
We are exposed to market risk from changes in interest rates which could affect our financial condition and results of operations. We have not entered into derivative contracts for our own account to hedge against such risk.

INTEREST RATE RISK
 
Fluctuations in interest rates may affect the fair value of financial instruments. An increase in market interest rates may increase interest payments and a decrease in market interest rates may decrease interest payments of such financial instruments. We have no debt obligations which are sensitive to interest rate fluctuations as all our notes payable have fixed interest rates, as specified on the individual loan notes.
 
ITEM 4.   CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
 
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, as appropriate, to allow timely decisions regarding required disclosure. Our management, with the participation and supervision of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report and determined that our disclosure controls and procedures were effective.
 
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
 
No changes of internal control over financial reporting were made in the threesix months ended SeptemberJune 30, 2014.2015.

INHERENT LIMITATIONS ON EFFECTIVENESS OF CONTROLS
 
Our management, Ronald Kempers, who is now both CEO and CFO, does not expect that our disclosure controls or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the company have been detected.
 
These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

 
1615
 
 
PART II.   OTHER INFORMATION

ITEM 1.   LEGAL PROCEEDINGS

Neither we, nor our wholly owned subsidiaries 6543 Luxembourg S.A., Mymetics S.A., Bestewil Holding B.V. nor its subsidiary Mymetics B.V. are presently involved in any litigation incident to our business.

ITEM 1A.   RISK FACTORS

Not applicable.

ITEM 2.   UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3.   DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.   MINE SAFETY DISCLOSURES

None.

ITEM 5.   OTHER INFORMATION

None.

ITEM 6.   EXHIBITS
 
EXHIBIT NUMBERNUMBER DESCRIPTION
   
31.1
 Rule 13a-14(a)/15d-14(a) Certification of Chief
   
31.2
 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
   
32
 Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
   
101.INS Instance Document
   
101.SCH XBRL Taxonomy Extension Schema Document
   
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
   
101.LAB XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
 
 
1716
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 MYMETICS CORPORATION 
    
Dated:  November 13, 2014August 14, 2015By: /s/ Ronald Kempers 
  Chief Executive Officer / Chief Financial Officer
    
 
 
 
1817